BioCentury on BioBusiness,
Tools & Techniques
Monday, November 8, 1999
When Cornell University researchers published in Nature last May that pollen from Bt corn posed a risk to Monarch butterflies, the laboratory study was used as an emotional rallying point for anti-biotech activists. Further research suggests a negligible risk of butterfly toxicity from the genetically modified crop. But despite the overall conclusion of last week's Monarch Butterfly Research Symposium in Rosemont, Ill., that Bt pollen is not a significant risk, the case is not yet airtight.In a University of Guelph (Ontario) study presented at the symposium, for example, Bt pollen was found primarily within 5 meters of the edge of a Bt corn field. However, the dense pollen found within that region was found to be toxic to Monarch larvae, providing grist for the defenders of the Cornell research
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]